Trump Announces 100 Percent Tariff on Imported Drugs Starting October 1

President Donald Trump has announced that the United States will put a 100 percent tariff on some imported drugs starting October 1. The decision mainly targets branded and patented medicines that are made outside the U.S.

According to Trump, this step is meant to bring more pharmaceutical manufacturing back to the United States and reduce dependence on foreign suppliers. The new tariff will not apply to companies that are already building drug production plants in America. If a company has started construction, it may be exempt from the new rules.

What Drugs Will Be Affected?

The tariff is aimed at branded or patented medicines, not generic drugs. Generic medicines, which are cheaper copies of brand-name drugs, are not directly targeted under this policy.

This move could affect patients and healthcare providers because many important medicines are currently imported from other countries. Industry experts say prices for some drugs may rise in the U.S.

Why Did Trump Take This Step?

Trump said the tariffs are designed to:

• Push pharmaceutical companies to manufacture in the U.S.
• Protect American industries and jobs
• Strengthen national security by reducing reliance on foreign supply chains

Reaction from Pharma Companies

• Roche, a Swiss drugmaker, highlighted that it has already started building a facility in North Carolina, which may protect it from the tariffs.
• Other large companies like Novartis also have U.S. operations that could limit the impact.
• In India, drug makers such as Sun Pharma, Cipla, and Dr. Reddy’s saw their stock prices drop after the announcement, with analysts warning that Dr. Reddy’s could be most affected.

Possible Impact on Americans

Experts warn that the 100 percent tariff may:

• Increase the cost of medicines in the U.S.
• Disrupt supply chains for life-saving drugs
• Add new pressure on the healthcare system
• Face legal challenges in U.S. courts

The policy has sparked concern among trade partners and could trigger disputes about whether such tariffs are fair or even legal.

Bottom Line

The new tariff on imported branded drugs is set to begin on October 1, 2025. While the Trump administration says the move will strengthen U.S. manufacturing, critics worry it may raise prices for patients and create challenges in the healthcare system.

This is a developing story, and more details are expected as the policy is implemented.